Neil Kumar - 16 Mar 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: CEO and President, Director
Issuer ticker: BBIO
Reported as of: 16 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2022, 16:26:11 UTC
Prior SEC filing: 18 Feb 2022
Next SEC filing: 18 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian C. Stephenson, Attorney-in-Fact

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 18 Mar 2022.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2022, 16:26.

Change

Previous filing in this sequence was filed on 18 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +489,456
Change %
Price: $0.000000
Shares after: 489,456
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 489,456
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

The RSUs will vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.